China Unveils Weight-Dependent Pricing for Hemophilia B Gene Therapy

BEIJING, China – July 30, 2025 – China’s National Medical Products Administration (NMPA) approved Xinjiuning (BBM-H901), a new gene therapy for adult patients with moderate to severe hemophilia B (congenital coagulation factor IX deficiency) in April. Now, new information from the China Pharmaceutical Innovation and Research Development Association (PhIRDA) reveals a unique weight-dependent pricing model and a charity initiative to mitigate costs.

Developed by Xinxin Pharmaceuticals and to be commercialized by Takeda in mainland China, Hong Kong, and Macau, Xinjiuning is a single-administration treatment priced at CNY 93,000 (approximately USD 12,800) per vial. For a typical patient weighing 70kg, this translates to 44 vials, bringing the total list price to over CNY 4 million (USD 560,000).

Recognizing the significant cost, Takeda and Xinxin Pharmaceuticals have stated they are “jointly carried out various active explorations and efforts” regarding payment for the product. They are “actively coordinating multiple forces to systematically promote and explore multi-level protection plans, hoping to alleviate the treatment difficulties faced by patients due to cost issues and allow the results of medical innovation to benefit more patients with rare diseases.”

In a notable effort to reduce the financial burden, the Beijing Pain Challenge Charity Foundation has launched the “Friendship” Love and Help Hemophilia Charity Aid Project. This national program will cap out-of-pocket expenditure for patients at CNY 2.79 million (approximately USD 388,696), equivalent to the cost of 30 vials. While well-intended, this remains a substantial amount for the average Chinese earner.

This payment approach exemplifies China’s latest pro-innovation pricing and policy initiatives. Earlier this month, the National Healthcare Security Administration (NHSA) initiated the submission process for the first edition of the Commercial Health Insurance Innovative Drug List. This new catalog aims to include drugs that fall outside the criteria for the basic National Reimbursement Drug List (NRDL), signaling a broader effort to expand access to innovative, often high-cost, therapies.